ACTRN12620000640909招募中未知
A phase II, open label non-randomised clinical trial of the safety and efficacy of the CovidCare app to support self-monitoring for COVID-19 symptoms in self-isolation and to determine the impacts on mental health
niversity of Melbourne0 个研究点目标入组 200 人开始时间: 2020年6月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Aged 18 years and above presenting at the University of Melbourne health service, primary care clinic or designated respiratory clinic for Covid-19 testing.
排除标准
- •1.Patients aged under 18 years
- •2.Patients with existing conditions: lung and respiratory related diseases, heart conditions, type 1 or 2 diabetes are excluded from app usage until they have undertaken a medical review with their general practitioner or usual medical care provider
- •3.Patient requiring Prednisolone > 10mg daily for more than 2 weeks
- •4.Patient requiring immunosuppression to manage chronic disease including vasculitis, autoimmune disease, transplantation or inflammatory condition
- •5.Patient with known malignancy who is or has received chemotherapy, immunotherapy, targeted antibody therapy or radiotherapy within 3 months from Covid 19 diagnosis
- •6.Patient with acquired or genetic immunodeficiency who require regular intravenous immunoglobulin therapy
- •7.Patient with asthma who has been prescribed targeted therapy including anti IgE therapy (omalizumab)or anti Il 5 therapy (mepolizumab, benralizumab).
研究者
相似试验
进行中（未招募）
不适用
The objective of the study is to understand if the association of the two drugs (trastuzumab and lapatinib), who both have as target the HER2 receptor with different mechanisms of action, can increase the chance of hitting the tumor compared to the association of trastuzumab to standard chemotherapy treatment, slowing or stopping the growth of cancer cells.HER2-positive metastatic breast cancer (MBC) refractory to anti HER2 therapiesMedDRA version: 17.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-005044-29-ITConsorzio Oncotech
进行中（未招募）
不适用
An open-label, randomized, controlled Phase-II trial evaluating the efficacy and safety of EndoTAG-1 in triple receptor negative breast cancer patientsEUCTR2006-002221-23-BEMediGene AG135
进行中（未招募）
不适用
An open-label, randomized, controlled Phase-II trial evaluating the efficacy and safety of EndoTAG-1 in triple receptor negative breast cancer patientsFemale patients with triple negative breast cancerMedDRA version: 8.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2006-002221-23-FRMediGene AG135
进行中（未招募）
不适用
An open-label, randomized, controlled Phase-II trial evaluating the efficacy and safety of EndoTAG-1 in triple receptor negative breast cancer patientsFemale patients with triple negative breast cancerMedDRA version: 8.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2006-002221-23-DEMediGene AG135
进行中（未招募）
1 期
Posaconazole (MK-5592) IV and oral in children with invasive aspergillosisEUCTR2019-002267-10-GRMerck Sharp & Dohme LLC30